We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Brand, Generic-Drug Makers Differ Over Patent Reform Legislation
Brand, Generic-Drug Makers Differ Over Patent Reform Legislation
February 15, 2011
The Senate Judiciary Committee has once again passed Sen. Patrick Leahy’s (D-Vt.) Patent Reform Act and the bill is causing a split between the brand- and generic-drug industries.